Prevention & lipidsCohort study
Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study
- Prospective cohort study
- observational
Authors' conclusion
Treatment of FH from childhood/adolescence reduces the cumulative LDL-C burden compared with later onset treatment from adulthood in affected parents and permits attainment of LDL-C levels close to non-FH individuals; this finding was associated with the observation of a reduction in the cardiovascular risk of young FH patients.
Study context
- Population
- Children/adolescents with genetically confirmed heterozygous familial hypercholesterolaemia (FH), their non-affected relatives and FH parents (SAFEHEART)median follow-up 12.4 years
- Participants
- 348 / 165 / 288
- Exposure
- FH treated from childhood/adolescence vs FH parents vs non-FH relatives
- FH-Chn = 348
- non-FH-Chn = 165
- FH parents (FH-P)n = 288reference
- Outcome
- Impact of CLM, LDL-C burden and CV events
Main finding
As reported in the abstract
Values
Median LDL-C change FH-Ch −2.60 mmol/L, −47.4%
Median LDL-C burden by age 30-40 years FH-Ch 5909.0 mg/dL*years · FH-P 10 206.8 mg/dL*years
CV events by age 39 years FH-Ch 0.3% · non-FH-Ch 0.0% · FH-P 5.2%
On CLM at follow-up FH-Ch 84.5% · non-FH-Ch 4.2% · FH-P 95.1%
Median age at CLM start FH-Ch 14.5 · FH-P 36.1 years
LDL-C change FH-P −4.72 mmol/L, −67.6%
Observational data: associations, not effects.
Original publication
Summarised from the published abstract; every number is checked against it